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Didehydrothymidine (d4T)-Resistant Mutants of Feline 
Immunodeficiency Virus (80 pp) 
Director: Thomas W. North 
A step-wise selection protocol was used to obtain two 
mutants of feline immunodeficiency virus (FIV) resistant to 2',3'-
dideoxy-2',3'-didehydrothymidine (d4T). These mutants were 
selected by passage of FIV 34TF10 (a molecular clone of FIV 
Petaluma) in Increasing concentrations of d4T, beginning at 12.5 |J.M 
in the initial round and increasing the concentration 2-fold in each 
subsequent round. Two mutants able to replicate in 100 fiM d4T (8 
times of the IC50) were obtained and plaque-purified. 
Both mutants were 3 to 4-fold resistant to d4T, relative to 
FIV 34TF10. These mutants were cross-resistant to 3'-azido-3'-
deoxythymidine (AZT), 3'-fluoro-2',3'-dideoxythymidine (FLT), 2',3'-
d ideoxycyt id ine (ddC),  2 ' ,3 ' -d ideoxy inos ine (dd l ) ,  9- (2-
phosphonylmethoxyethyl)-adenine (PMEA), and were highly resistant 
to phosphonoformic acid (PFA). The mutant phenotype was stable, as 
the virus remained d4T-resistant even after passage in the absence 
of d4T for three rounds. Reverse transcriptase (RT) was purified 
from one of these mutants, D4R-3c. This RT was 5-fold resistant to 
the 5'-triphosphate of d4T (d4TTP), relative to wild-type FIV RT. 
Sequence analysis of the RT-encoding region of the pol gene revealed 
a point mutation at position 2474 resulting in a Val to lie mutation 
at amino acid 47 of the FIV RT. Site-directed mutagenesis was 
performed and showed that this amino acid change was responsible 
for the d4T-resistance. 
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INTRODUCTION 
GENERAL INTRODUCTION 
In the nnid-1980s, announcements in Paris and in Bethesda, 
Maryland, declared that a retrovirus had been isolated that was the 
etiologic agent of the acquired immune deficiency syndrome (AIDS) 
which poses a serious challenge to modern medicine. The retrovirus 
is known today as the human immunodeficiency virus type-1 (HIV-1). 
The virus targets cells of the immune system, specifically the 
helper T lymphocytes. HIV infection results in immunosuppression, 
rendering the patient susceptible to opportunistic infections. These 
infections lead to a high incidence of morbidity and mortality (40). 
HIV-1 is currently the number two killer of people between the ages 
of 25 and 45 years. Over 13 million people are presently infected 
with the virus and predictions for the future are frightening (50). To 
conquer this disease, two strategies have been undertaken: a 
protective vaccine or effective drugs able to block the life cycle of 
the virus. It is widely agreed that an AIDS vaccine is necessary, but 
this virus is in a state of antigenic flux, and consequently, 
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protective vaccine development has been difficult. To date, no 
protective vaccine has been developed. In contrast, modest success 
has been achieved with chemotherapy. Antiviral agents are usually 
targeted at a receptor, enzyme or another viral component that is 
required for replication. There are various events in the replicative 
cycle of HIV that could be considered as targets for 
chemotherapeutic intervention: 1) virus adsorption to the cell 
membrane; 2) fusion between the viral envelope and the cell 
membrane; 3) uncoating of the viral nucleocapsid; 4) reverse 
transcription of the viral RNA to proviral DNA; 5) integration of the 
pro viral DNA into the cellular genome; 6) transcription of the 
proviral DNA to RNA, a process that is regulated by transcriptional 
transactivators (i.e., TAT); 7) conversion of the viral precursor 
mRNA to mature mRNA, a process that is regulated by 
posttranscriptional transactivators (i.e., REV); 8) posttranslational 
processing of the viral precursor proteins by proteolysis, 
glycosylation, and myristoylation; and 9) virion assembly and 
release ("budding") (12, 44). To date, numerous compounds have been 
reported to inhibit the replication of HIV in vitro, yet only relatively 
few agents have at this time been formally licensed (in the United 
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States) for clinical use in the treatment of AIDS. These are 
zidovudine (3'-azido-2',3'-dideoxythymidine, AZT) (34), didanosine 
(2',3'-dideoxyinosine, ddl) (17), zaicitabine (2',3'-dideoxycytidine, 
ddC) (73), stavudine (2',3'-didehydro-2',3'-dideoxythymidine, d4T) 
(2) and (-)-B-2',3'-dideoxy-3'-thiacytidine (3TC) (55). Several 
protease inhibitors have been approved also. However, variants of 
HIV-1 that are resistant to these drugs, or combinations of these 
drugs, emerge in treated patients and are believed to be responsible 
for drug failures (18,35,59,63,64,71). The problem of resistance is 
not limited to nucleoside analogs. Mutants of HIV-1 resistant to 
non-nucleoside inhibitor of RT, such as nevirapine (60), or to 
protease inhibitors (10,28) have been isolated from treated patients. 
Numerous HIV-1 mutants resistant to RT or protease inhibitors have 
also been selected in cell culture systems (19,20,30,36,51). 
Resistance of HIV-1 to RT and protease inhibitors has been traced to 
mutations in genes encoding the HIV-1 RT and protease, respectively 
(62). In order to develop successful AIDS therapy, it will be 
necessary to understand mechanisms of resistance and to develop 
strategies to combat it. 
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Animal models of AIDS are essential for understanding the 
pathogenesis of retrovirus-induced immune deficiency and 
encephalopathy, and for development and testing of new therapies 
and vaccines. Many viruses and animal models have been evaluated 
for use as AIDS models, including simian immunodeficiency virus 
(SIV), avian retroviruses, murine retroviruses, severe combined-
immunodeficiency (SCID) mouse models, lentiviruses in sheep, goats, 
horses and cows, HIV type-2 (HIV-2) infection in macaques, and 
feline immunodeficiency virus (FIV) infection of cats. Since its 
discovery in 1987 (53), FIV has become recognized as a valuable 
animal model for AIDS studies. The advantages of this model are 1) 
the FIV biology, infection cycle, and disease closely mimic those of 
HIV and human AIDS, 2) cats are relatively inexpensive compared to 
nonhuman primates, 3) FIV is safe to work with since it is not 
infectious to human, and 4) in vitro and in vivo systems are 
available and their versatility facilitates studies of pathogenesis, 
antiviral therapies, protective vaccines, and drug resistance. 
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FELINE IMMUNODEFICIENCY VIRUS 
Feline immunodeficiency virus (FIV) is a lentivirus that causes an 
immune deficiency in domestic cats that is very similar to human 
AIDS and which can also be induced experimentally in specific-
pathogen-free cats (SPF) (70,74). FIV was first described by Neils 
Pedersen and co-workers in 1987. Subsequent investigations have 
shown that FIV is an important health problem for domestic cats 
throughout the world. The expectation that FIV would become a 
leading animal model for HIV studies has been fulfilled. 
The virion. The mature extracellular FIV virion is spherical to 
ellipsoid, 100 to 125 nm in diameter, and bordered by an outer 
envelope with poorly defined short projections or knobs. The 
elongated core is composed of a conical shell that surrounds an 
eccentric electron-dense nucleoid. A polygonal electron-lucent halo 
is often visible between the core and a granular layer found just 
inside the envelope (45,53,69,75). Each FIV virion contains: the 
envelope (Env) glycoproteins: surface (SU) protein, and 
transmembrane (TM) glycoprotein; the internal protein (Gag) 
components: the matrix (MA) protein, capsid (CA) protein and 
nucleocapsid (NC) protein; and the Pol proteins including protease 
(PR), RT, dUTPase (DU) and integrase (IN). FIV virions also contain 
two copies of the positive-stranded, polyadenylated RNA genome 
(about 9200 bases long). As is typical of retroviruses, in the FIV 
virion Gag proteins are about 20-fold more abundant than Pol 
proteins (16) (Fig.1). 
Life cycle. FIV is an enveloped, single-stranded RNA virus that 
belongs to the lentivirus family. FIV and HIV-1 share the 
prototypical life cycle of a retrovirus (Fig. 2). The virus is first 
adsorbed by a receptor on the host cell membrane. HIV binds to T 
cells surface receptor, the CD4 molecule (CD9 in FIV), and by 
interacting with this and at least one other cell surface 
molecule, a conformational change occurs in the envelope 
glycoproteins to reveal the hydrophobic sequence of the 
transmembrane envelope protein. This leads to a fusion of the viral 
envelop with the cell membrane and delivery of the viral capsid into 
the cytoplasm of the cell (38). Within the capsid structure the 
diploid RNA genome is reverse transcribed by the viral RT. RT is the 
viral-encoded RNA-dependent DNA polymerase responsible for 
synthesis of a DNA copy of the viral RNA genome. This generates an 
RNA/DNA heteroduplex containing a complete DNA copy of the viral 
genes. Subsequently, the RNA is degraded by the RNase H activity of 
RT, and a DNA duplex is synthesized by RT. The double-stranded DNA 
genome is then integrated into the host genome as a provirus (68). 
The provirus may remain dormant until some, as of yet unknown, 
factor(s) stimulates the provirus into active replication to produce 
infectious virus particles. The cell will then produce viral RNA and 
proteins. These progeny viruses assemble and are released from the 
cell surface by budding. The virus can then infect other cells. 
Genome structure and organization. FIV diverges from other 
lentiviruses throughout the genome. Its sequence organization, 
however, is similar in complexity to that of other lentiviruses 
(Fig.3). Three large open reading frames (ORFs), gag, pol, and env, 
encode the internal structural proteins , the RT and other viral 
enzymes, and the envelope proteins, respectively. FIV also has 
several small ORFs that encode regulatory proteins. The provirus 
contains two long terminal repeat (LTR) elements, one at each end of 
the genome, which accommodate multiple regulatory sequences. 
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The gag gene, spanning approximately nucleotides 600 to 2000, is 
initially translated to yield a precursor polypeptide of about 50 kDa 
that is posttranslationally cleaved by the viral protease (PR) (14,65) 
to yield (amino to carboxy order) three functional core proteins. 
They are mature MA, CA, and NC proteins. The MA is approximately 
15 kDa , which has recently been shown to be myristoylated (16). 
The CA protein is the largest gag product. It is the major core 
protein, a 25 kDa group-associated antigen. The NC protein is 
1 1  
approximately 10 kDa, which contains motifs characteristic of 
retroviral nucleic acid binding proteins and is believed to be 
associated with the genomic RNA to form the ribonucleoprotein 
(14,65). 
The pol gene is an enzyme cassette, which spans nucleotides 
1900 to 5200 and, thus, overlaps the gag gene by 109 nucleotides. 
Pol is in a -1 reading frame with respect to that of the gag gene 
and is translated as a Gag-Pol fusion polyprotein produced by 
ribosomal frameshifting (8), as in other retroviruses. The Gag-Pol 
fusion precursor protein is eventually processed into the 
functionally mature enzymes during virus assembly. The Pol portion 
of the precursor polyprotein is eventually cleaved into PR, RT, DU, 
and an endonuclease or integrase, most likely due to autodigestion 
(15,16). 
The primary translation product of the env gene (which spans 
nucleotides 6250 to 8850) is a precursor glycoprotein of 145 to 150 
kDa (gp145) that is rapidly reduced in size to a molecule of 139 kDa 
(gp130). gp130 is subsequently processed into the mature 
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glycoproteins SU (gp95) and TM (gp40) of the viral envelope by 
proteolytic cleavage in the Golgi complex (66). 
Moreover, FIV also contains regulatory genes. The re y and vif are 
the only two that have been characterized to some extent. 
Biochemical features of RT. The RT of FIV has been purified 
and extensively characterized by North, et al. FIV RT consists of two 
polypeptides with common N-termini, a 66-kDa (p66), and a 51-kDa 
subunit. Both subunits are present in equimolar amounts (46,49). FIV 
RT p51 is generated by cleavage of the RNase H domain (pi 5) at the 
C-terminus of FIV RT p66 by the virus-encoded protease. FIV RT is 
very similar to HIV-1 RT in physical properties, catalytic activity 
and sensitivity to several RT inhibitors (11,47,48,49). Both enzyme 
have comparable requirements for Mg2+ and similar template 
specificities (49). From sequence analysis, HIV-1 RT and FIV RT 
share 63% identity at the nucleotide level and 48% identity and 67% 
similarity at the amino acid level, respectively (1). 
The first five antivirals approved for AIDS therapy are targeted 
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to RT. RT has become an excellent target for attempts to arrest the 
proliferation of HIV -1 for several reasons: a) it is a crucial enzyme 
in the viral replication cycle; b) its properties are quite different 
from those of the other cellular DNA polymerases; and c) it is active 
in the cytoplasmic compartment of the infected cell, separate from 
the nuclear and mitochondrial DNA polymerases. FIV and HIV-1 RTs 
are nearly identical in susceptibility to several nucleotide analogs 
that are active forms of antiviral drugs, including 2',3'-
dideoxythymidine 5'-triphosphate (ddTTP), AZTTP, 2',3'-
dideoxycytidine 5'-triphosphate (ddCTP), 2',3'-dideoxy-2',3'-
didehydrothymidine 5'-triphosphate (d4TTP). They are also similar 
in susceptibility to 3'-fluoro-3'-deoxythymidine 5'-triphosphate 
(3'-F-dTTP), 3'-amino-3'-deoxythymidine (3'-NH2-dTTP) and two 
noncompetitive inhibitors PFA and phosphonoacetate (PAA) (48). 
Because of the similarities of FIV and HIV-1 RTs, FIV has been 
extremely useful as a model for RT-targeted antivirals. 
Transmission and pathogenesis. In contrast to HIV-1, FIV is not 
efficiently transmitted sexually (54). FIV is usually spread through 
an infected cat biting or scratching an uninfected cat. 
Experimentally-infected female cats have been shown to transmit 
the virus to their offspring (72), although naturally-infected cats 
transmitting virus to offspring has not been reported. Interspecies 
transmission does not occur with FIV. This species specificity of 
FIV is characteristic of retroviruses. No FIV antibodies have been 
detected in humans who have had extensive contact with FIV-
infected cats, including individuals who have been bitten. This 
shows that FIV is a safe model for AIDS studies. 
The pathological effects observed in FIV-infected cats may be 
both a direct consequence of FIV infection and secondary to the 
immunodeficiency state caused by the virus. From observations of 
field and experimentally-infected SPF cats, it has become evident 
that FIV infections can be divided into several sequential steps. On 
the basis of the type and severity of clinical signs, a staging of FIV-
infected cats into five phases which parallels the classification 
systems used for HIV-induced pathology, a) Acute phase. In some 
cases primary infection is clinically silent. More commonly, it 
manifests itself as a transient illness (1 to 4 weeks) with 
generalized lymphadenopathy, mild pyrexia dullness, neutropenia , 
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acute diarrhea, and mild upper respiratory symptoms (8). b) 
Asymptomatic phase. During this latent stage of infection, virus can 
be isolated from the blood, but no clinical signs are apparent, c) 
Persistent generalized lymphadenopathy (PGL). In this stage the 
animal exhibits vague signs of disease, including recurrent fevers, 
anorexia, weight loss, or nonspecific behavioral changes but without 
any obvious indications of secondary or opportunistic infections, d) 
AIDS-related complex (ARC). Cats in this category usually present 
with chronic secondary infections of the oral cavity, upper 
respiratory tract, and other body sites but no opportunistic 
infections. Most cases diagnosed as ARC progress to feline AIDS 
(FAIDS) after variable time intervals (26,27,52). e) FAIDS. It is 
similar in many respects to full-blown AIDS of humans. Cats suffer 
from severe secondary infections listed above and from neoplastic 
and neurologic disorders. Infections are often multiple, sustained by 
opportunistic agents, and resistant to treatment. Most animals 
present with a marked loss of body weight as well as severe anemia 
and leukopenia. The clinical picture worsens rapidly, and once the 
diagnosis is made, the mean survival time is usually less than 1 
year, in spite of supportive therapy (27,52). In addition to the above 
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stages, Pedersen (52) has proposed a sixth group to include cats 
presenting with miscellaneous disorders (neurological, neoplastic, 
ocular, and immunologically mediated, etc.) in the absence of other 
manifestations that, if present, would allow their inclusion in the 
previous classification. 
Treatment. Currently available anti-HIV therapies are only 
partially effective in controlling virus replication. Since RT plays an 
important role in replication of both HIV-1 and FIV, it is an 
attractive target for antiviral chemotherapy. RT inhibitors can be 
divided into two groups, depending on whether they are targeted at 
the substrate binding site or nonsubstrate binding site (13). To the 
first group belong the 2',3'-dideoxynucleosides (i.e., ddC, ddl), 3'-
azido-2',3'-dideoxynucleosides (i.e.,AZT), 3'-fluoro-2',3-
dideoxynucleosides (i.e.,FLT), 2',3'-didehydro-2',3'-
dideoxynucleosides (i.e., d4T, d4C) and carbocyclic derivatives 
thereof (i.e., carbovir), 2'-fluoro-ara-2',3'-dideoxynucleosides, 1,3-
dioxolane derivatives (i.e., 2',3'-dideoxyl-3'-thiacytidine), 
oxetanocin analogues and carbocyclic derivatives thereof (i.e., 
cyclobut-G) and the PMEA and 9-(3-fluoro-2-
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phosphonylmethoxypropyl)adenine (FPMPA) derivatives. These 
compounds need to be phosphorylated intracellularly to their 
triphosphate forms before they act as competitive inhibitors or 
alternate substrates (chain terminators) of RT (Fig.4). The second 
group includes the tetrahydro-imidazo[4,5,l-jk][1,4]-benzodiazepin-
2(1H)one (TIBO), 1-[(2-hydroxyethoxy)-methyl]-6-
(phenylthio)thymine (HEPT), djpyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-
one (nevirapine) and pyridin-2(1 H)one derivatives, which interact as 
such, noncompetltively, with a specific allosteric binding site of 
HIV-1RT. Members of this group do not inhibit FIV. 
In addition, several protease inhibitors are also being studied. To 
date, the FDA has approved five nucleoside analogs (AZT, ddl, ddC, 
d4T and 3TC) and two protease inhibitors for treatment of humans 
with AIDS. Since both HIV-1 and FIV RT are susceptible to the 
nucleoside analog inhibitors, FIV is an excellent choice as an animal 
model for drug resistance studies of viral mutants resistant to 
these drugs. 
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Fig 4. Nucleoside and pyropliospliate analogs with antiviral 
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Drug resistance. The rapid emergence of drug-resistant 
variants of HIV-1 is a significant impediment to the treatments of 
AIDS. Clinically, drug-resistant mutants arise in AIDS patients 
treated with nucleoside analogs, protease inhibitors, etc. The first 
reported lentivirus mutants with drug-resistant phenotypes that 
were selected in vitro were AZT-resistant mutants of FIV (57). 
These mutants were phenotypically similar to AZT-resistant 
mutants of HIV-1 isolated from patients (35,57). Mutants of FIV that 
are resistant to ddl (21), ddC (43) or the combination of AZT plus ddl 
(21) have been subsequently reported. Resistance to AZT, ddC have 
been traced to mutations within the RT-encoding region of the pol 
gene (58,43). 
The d4T is a thymidine analogue with an unsaturated bond 
between the 2'- and 3'-carbons of the sugar moiety. Like AZT, it is a 
potent inhibitor of HIV replication in several cell lines and prevents 
the cytopathic effects of the viral infection (4,5,6,25,39,40,41). d4T 
is metabolized in cells to the triphosphate form (d4TTP), which is a 
potent inhibitor of the viral RT in a manner that is competitive with 
respect to the natural substrate, dTTP. D4TTP also serves as a 
2 0  
substrate for incorporation into DNA, whicli causes chain 
termination (24). d4T has shown efficacy in patients with AIDS and 
is less toxic to host cells than AZT (22,40,41,42). Cells take up d4T 
by nonfacilitated diffusion (3) and then phosphorylate it by cellular 
enzymes to its mono-, di-, and triphosphates. Unlike AZT, d4T has a 
low affinity to thymidine kinase in several cell lines (6,42). Thus, 
the conversion to its monophosphate by this enzyme is the rate-
limiting step in its metabolic activation pathway by triphosphate 
(25,42). 
There are no clinical reports in the literature of documented 
mutations in the HIV-1 RT conferring decreased sensitivity to d4T. 
Clinical isolates highly resistant to AZT were found to remain 
sensitive to d4T (35). Furthermore, recombinant viruses resistant to 
AZT, ddl, ddC or 3TC are not cross-resistant to d4T (33). In view of 
the clinical potential of d4T, it is important to determine how 
readily viral resistance is likely to arise and what cross-resistance 
to other inhibitors might be expected. Lacey and Larder have 
selected mutants of HIV-1 that are resistant to d4T in vitro (33). 
These variants have a mutation at codon 75 in the RT-encoding 
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region of the HIV-1 pol gene that results in substitution of Thr for 
Val-75 of the HIV-1 RT. This mutation confers moderate (seven­
fold) d4T-resistance and cross-resistance to both ddl and ddC. 
In order to study drug resistance, it is important to have a 
defined system that is safe and easily manipulated. It is also useful 
to have a system which allows for timely selection of drug-
resistant mutants. FIV has a well-defined cell culture system and 
drug-resistant mutants can be readily selected (59). In addition, 
there is a molecular clone of FIV, FIV 34TF10, with a known 
sequence (67). This molecular clone provides a defined genetic 
system to study mutations. Using FIV as an animal model, many 
questions pertaining to drug resistance can be addressed. Not only 
can drug-resistant mutants be selected and characterized in a cell 
culture system, but the pathogenicity and infectivity of drug-
resistant mutants can be determined in cats (7). In the work 
described here we have utilized the FIV system to characterize 
resistance to d4T. 
SPECIFIC GOALS 
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The goal of this study was to select and characterize d4T-
resistant mutants of FIV 34TF10. Specific objectives were to select 
variants of FIV that appear when virus replication occurs in the 
presence of d4T, to determine whether these mutants are cross-
resistant to other antivirals, and to determine whether d4T-
resistance is due to alterations in RT by characterization of RT 
purified from the mutant and by DNA sequence analysis and site-
directed mutagenesis. 
MATERIALS AND METHODS 
CHEMICALS. Triton X-100, dTTP, aminoethyl carbazole, ddC and 
phosphonoformic acid (RFA) were purchased from Sigma Chemical 
Co., St. Louis, MO. AZT and the 5'-triphosphate of AZT (AZTTP) were 
provided by the Burroughs Wellcome Co., Research Triangle Park, NC. 
The d4T and the 5'-triphosphate of d4T (d4TTP) were provided by 
Bristol-Myers Squibb Co., Wallingford, CT. PMEA was provided by 
Gilead Sciences, Inc., Foster City, CA. The ddl was provided by the 
Developmental Therapeutics branch. Division of AIDS, National 
Institute of Allergy and Infectious Diseases. The 3'-fluoro-2',3'-
dideoxythymidine (FLT) was obtained form the Lederle Laboratories 
Division of American Cyanamid Co., Pearl River, NY. Poly (rA)-
oligo(dT)io was purchased from Pharmacia LKB, Piscataway, NJ. 
Nuclease-free bovine serum albumin (BSA) was obtained from 
Boehringer Mannheim, Indianapolis, IN. DEAE-cellulose DE52 and 
phosphocellulose P11 were purchased from Whatman, Hillsboro, OR. 
International Bio Technologies (IBI) phenol for DNA extractions was 
purchased from VWR Scientific. GeneAmp PCR Core 
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Reagents were purchased from Perkin Elmer Cetus, Norwalk, CT. The 
Taq DyeDeoxyTM Terminator Cycle Sequencing Kit was purchased 
from Applied Biosystems, Foster City, CA. EcoRI was purchased 
from Promega, Madison, Wl. and A/s/l was from American Applied 
Biotechnology, Aurora, CO. T4 DNA ligase was from New England 
Biolabs, Beverly, MA. All other chemicals were reagent grade or 
better. 
ISOTOPE. The [Methyl-3H]dTTP was purchased from Dupont-New 
England Nuclear, Boston, MA. 
CELLS AND VIRUS. Virus produced from a molecular clone of the 
Petaluma strain of FIV, 34TF10 (67), was used as wild-type FIV for 
these studies. Wild-type and mutant strains of FIV were grown and 
maintained in Crandell feline kidney (CrFK) cells. Uninfected and 
infected cells were grown in L & M medium which was composed of 
equal parts of Leibovitz L-15 and Dulbecco's Modified Eagle Medium 
(Gibco BRL Life Technologies, Inc. Grand Island, NY.), supplemented 
with 100 U of penicillin per ml, 100 jig of streptomycin per ml, 2.0 
mM L-glutamine and 10% fetal bovine serum (FBS). FBS was heat 
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inactivated for 30 min. at 56°C. All cultures were maintained at 
37°C in a humidified 5% CO2 atmosphere. The CrFK cells used were 
passaged 6 or fewer times after they were obtained from the 
American Type Culture Collection (Rockville, MD.) because we have 
observed that at high passage number in L & M medium these cells 
lose ability to support FIV replication (32). The d4T-resistant 
mutants of FIV were maintained in medium containing d4T, and the 
medium was replaced with fresh medium containing the appropriate 
concentration of d4T every 2 days. 
Virus stocks were prepared from medium containing extracellular 
virus released from CrFK cells that had been infected with FIV for 
more than 21 days. Medium was removed from cultures that were 
near confluence and cells were removed from the medium by 
centrifugation at 500 X g for 10 min. The supernatant was stored at 
-80°C in medium containing 10% dimethyl sulfoxide. Aliquots of 
these stocks were thawed and used to infect CrFK cells for 
subsequent studies. 
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FOCAL INFECTIVITY ASSAY (FIA). The FIA was developed in this 
lab by Remington et al. (57) and is a modification of the FIA 
developed by Chesebro and Wehrly to quantitate HIV-1 (9). In this 
assay, CrFK cells were seeded into 24-well plates at a density of 
1.5 X 104 cells per well and incubated for 1 h at 37°C in growth 
medium or growth medium containing appropriate concentration of 
drug. This incubation was to allow the cells to convert drugs to their 
active forms. These cells were infected with 30 to 60 focus-
forming units (FFU) of wild-type or mutant FIV per well, then 
incubated at 37°C for 4-5 days to allow cells to grow to confluence. 
The medium was replaced with fresh medium and appropriate drug 
concentration every 2 days. When the cells reached confluence, the 
medium was aspirated and the cells were fixed with methanol for 
five minutes. The cells were then washed twice with TNE (0.01 M 
Tris-HCI, pH 7.5, containing 0.15 M NaCI and 0.002 M EDTA), and once 
with TNE that contained 1% adult bovine serum. Immunostaining was 
performed by incubating the fixed cells for 30 min with 0.2 ml of a 
1/200 dilution of polyclonal antiserum that had been obtained from 
FIV-infected specific-pathogen-free cats. Cells were washed twice 
with TNE that contained 1 % serum to remove excess antiserum and 
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were then incubated for 40-60 min with 0.2 ml of a 1/600 dilution 
of horseradish peroxidase-conjugated goat anti-cat IgG (Organon-
Teknika, Durham, NC ). The cells were again washed with TNE and 
foci of infected cells were then stained by reacting the antibody-
bound monolayers for 20 min in the dark with a solution of 
aminoethyl carbazole (1 part 4 mg/ml aminoethyl carbazole in 
dimethylformamide per 19 parts 0.05 M sodium acetate buffer, pH 
5), containing 30% H2O2 (1 M-l per 2 ml). After incubation, the cells 
were rinsed three to five times with water and allowed to dry. Foci 
appeared as groups of 4 or more infected cells (red), which is 
defined as a focus of infection, against an unstained background. 
Foci were examined and counted under a dissecting microscope at 10 
to 40 X magnification. For visualization, light was reflected off a 
piece of ground glass to reduce the refractivity of the infected cells. 
For dose response curves with drugs, data were plotted as 
percentage of control plaques (no drug) versus inhibitor 
concentration. Concentrations required to inhibit focus formation by 
50% (IC50 values) were obtained directly from the linear portion of 
these plots. 
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SELECTION OF d4T-RESISTANT MUTANT. A step-wise selection 
protocol that is similar to that used by Gao et al. (19,20) and by 
Larder et al. (36) to select drug-resistant variants of HIV-1 was 
chosen. The initial round of selection was carried out with 12.5 iiM 
d4T, which is equivalent to the IC50 of d4T for FIV (58). The 
concentration of d4T was then increased 2-fold in each subsequent 
round. For the first round, two 25-cnn2 flasks of CrFK cells at 60% 
confluence (about 2 XI06 cells) were pre-treated for one hour with 
12.5 |j.M d4T to enable conversion of the drug to the active form. 
Then CrFK cells were infected with a cell-free culture supernatant 
of FIV 34TF10 at an input multiplicity of approximately 2000 focus 
forming units (FFU). Medium and drug were replaced every 48 hours, 
and cells were removed with trypsin and subcultured as necessary. 
The cultures were monitored weekly for the presence of virus by the 
FIA. By 2 to 3 weeks post-infection virus production was apparent. 
Culture supernatants from each of the first-round cultures were 
used to infect flasks of CrFK cells for the second round of selection 
in the presence of 25 fiM d4T. Using these protocols, virus was 
subsequently passaged in 25, 50, and 100 jiM d4T. In each round of 
selection, virus production was apparent by 2 to 3 weeks post-
infection. After passage in 100 iiM d4T (which is approximately 8 
times the IC50 for FIV), two d4T-resistant mutants, D4R-1c and 
D4R-2C were obtained. These mutants were subsequently plaque-
purified. 
Another selection protocol called "blast" selection was 
attempted. It is essentially as described by Remington et al. (57). 
Infections were carried out in the continuous presence of d4T at 100 
|xM, which is 8 times the IC50 for inhibition of FIV replication. Using 
this approach, AZT, ddl and ddC-resistant mutants of FIV have been 
successfully selected in the presence of drugs at concentrations 5 
to 10 times higher than the IC50. 
PLAQUE-PURIFICATION OF d4T-RESISTANT MUTANTS. To 
minimize potential heterogeneity within the d4T-resistant mutant 
populations, plaque-purified isolates were obtained from D4R-1c 
and D4R-2C. Plaque-purification of the mutant virus was carried out 
with a modification of the procedure described by Remington et. al. 
(58). Virus of both D4R-1c and D4R-2c were plaque-purified using 
limiting dilutions of virus in the FIA. Limiting dilutions of virus 
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were used to infect CrFK cells in 24-well plates in the presence of 
100 |iM d4T. After 5 to 6 days, each supernatant was transferred to 
a well of a new plate which had been seeded with uninfected CrFK 
cells at 30% confluence in the presence of 100 |iM d4T. The original 
plate was stained and examined for those wells that contained a 
single focus. Corresponding wells of the subculture plate were 
incubated until the cells reached confluence. The cells and 
supernatant from each well which contained a single focus were 
transferred to flasks and maintained in medium containing 100 jilVI 
d4T. Cultures were maintained by replacing medium and drug every 
two days. When they reached 100% confluence, cultures were 
monitored for virus production by FIA. Several cultures yielded 
virus. One from each of D4R-1c and 2c, designated D4R-3c and D4R-
4c, were used for further characterization. 
REVERSE TRANSCRIPTASE (RT). Reverse transcriptase (RT) was 
purified from virions of FIV 34TF10 and mutant FIV by a method 
developed by North et al. (49). FIV-infected CrFK cells were grown in 
225-cm2 tissue culture flasks to confluence. Culture medium 
containing virus was collected, cells were removed by 
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centrifugation at 500 X g for 5 min, ttien the virus pelleted by 
centrifugation at 41,000 X g for 60 min. The supernatant was 
discarded and the pellet resuspended in 50 mM Tris-HCI, pH 7.9, 20 
mM dithiothreitol (DTT), 160 mM KCI, 0-05% Triton X-100 to disrupt 
virions. Nuclease-free BSA was added to a final concentration of 
500 |ig/ml, and this virus lysate was stored at -80°C until 
purification. For purification, the virus lysate was dialyzed three 
times against 500 ml of 50 mM Tris-HCI, pH 7.9, 1 mM EDTA, 1 mM 
DTT, 5% glycerol (buffer A) and then applied to a 1.5 X 30-cm column 
of DEAE-cellulose. The column was washed with buffer A, and then 
reverse transcriptase was eluted with a 150-ml linear gradient of 
0-500 mM NaCI in buffer A. Fractions containing peak RT activity 
were pooled, nuclease-free BSA was added to a final concentration 
of 500 |ig/ml, and this was dialyzed three times against 500 ml of 
50 mM Tris-HCI, pH 7.9, 1 mM EDTA, 1 mM DTT, 20% glycerol, 50 mM 
NaCI (buffer B). This sample was then applied to a 1.5 X 30-cm 
column of phosphocellulose; the column was washed with buffer B, 
and then RT was eluted with a 150-ml linear gradient of 50-500 mM 
NaCI in buffer B. Peak fractions were pooled and stored at -80°C. 
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RT ACTIVITY ASSAY. During purification, RT was assayed for 
activity as reported previously (48,49) with poly(rA)-oligo(dT)io as 
the template-primer. Reactions were typically carried out in a 
volume of 50 |il and contained 50 mM Tris-HCI, pH 8.5, 10 mM DTT, 
0.05% Triton X-100, 250 jig of bovine serum albumin (nuclease-free) 
per ml, 6 mM MgCl2, 80 mM KCI, 20 |xM [methyl-3H]dTTP (33 jiCi/ml), 
0.5 A260 units (U) of poly(rA)-oligo(dT)io per ml, and appropriate 
amounts of RT. Samples containing 40 \i\ were taken at 30 min and 
spotted onto filters (no. 3, 2.3-cm diameter; Whatman, Inc., Clifton, 
NJ) that had been presoaked with 5% trichloroacetic acid (TCA)-1% 
sodium pyrophosphate (NaPPi). Filters were dried in an oven then 
washed four times (at least 1 hour each) with 5% TCA-1% NaPPi at 
4°C, twice with 95% ethanol at room temperature, dried in an oven 
and then counted in Liquifluor (Dupont-NEN Research Products, 
Boston MA). One unit of RT is defined as the amount of enzyme 
required to catalyze the incorporation of 1 nmol of dTMP per hour 
into poly (rA)-oligo(dT)io at 37°C. 
RT INHIBITION ASSAY. Inhibition of RT from the d4T-resistant 
mutant (D4R-3c) by d4TTP was compared to inhibition of wild-type 
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recombinant FIV RT. Double-reciprocal plots were used to determine 
kinetic constants (Km and Ki) with the template-primer poly(rA)-
oligo(dT)io and d4TTP as the inhibitor. Reactions were typically 
carried out in a volume of 50 |il and contained 50 mM Tris-HCI, pH 
8.5, 10 mM DTT, 0-05% Triton X-100, 250 )ig of bovine serum albumin 
(nuclease-free) per ml, 6 mM MgCl2, 80 mM KCI, varying amounts of 
[methyl-3H]-dTTP (16.5, 8.25, 4.95, 3.3, 2.45, and 1.65 jxCi/ml) 
corresponding to varying concentrations of dTTP (20, 10, 6, 4, 3, and 
2 |iM), 0.5 A260 U of poly(rA)-oligo(dT)io per ml, varying 
concentrations of d4TTP which were 0, 5, 10, 20 nM, and 
appropriate amounts of RT. Samples containing 40 p.! were taken at 
1 hour and spotted onto filters (no. 3, 2.3-cm diameter; Whatman, 
Inc., Clifton, NJ) that had been presoaked with 5% TCA-1% NaPPi (4° 
C) . Filters were washed with TCA four times (15 min each) and 
twice with 95% ethanol, dried and then counted in Liquifluor 
(Dupont-NEN Research products, Boston, MA). 
NUCLEIC ACID PREPARATION. Total cellular DNA containing 
provirus was extracted from CrFK cells that were infected with 
d4T-resistant FIV. Confluent monolayers of infected cells were 
3 4  
washed three times with TBS (25 mM Tris-HCI, pH7.4, containing 5 
mM KCI and 137 mM NaCI) and removed from flasks (cells peel from 
flask wall during the third wash). Cells were pelletted by 
centrifugation at 500 X g for 10 min. The cells were washed twice 
with TE (10 mM Tris-HCI, pH 7.6, containing 1 mM EDTA) then 
suspended in this TE buffer. Cell suspensions were treated with 0.1 
mg/ml proteinase K and 0.5% SDS overnight at 37° C. The cell 
lysates were then extracted three times with phenol that had been 
equilibrated with 10 mM Tris-HCI, pH 7.5, containing 100 mM NaCI 
and 1 mM EDTA. The aqueous phase was collected and dialyzed 
against 10 mM HCI, pH 7.5, containing 100 mM NaCI and 1 mM EDTA 
until the Aaeo of the dialysate was less than 0.1. The dialyzed 
aqueous phase was treated with RNase A (0.1 mg/ml) at 37° C for 3 
hours. The RNase A-treated aqueous phase was extracted with one-
half volume equilibrated phenol and one-half volume of 
chloroform:isoamyl alcohol (24:1). The aqueous layer was removed 
and extracted again with one volume of chloroform;isoamyl alcohol 
(24:1). The salt concentration was adjusted by adding 1/30 volume 
of 3 M sodium acetate, pH 5 to the aqueous phase. The DNA was 
precipitated with three volumes of cold absolute ethanol at -20° C 
overnight. The DNA was removed from the ethanol and dried in air. 
The DNA was dissolved in sterile distilled water and used for 
amplification by the polymerase chain reaction (PGR). 
PGR AMPLIFICATION AND NUCLEOTIDE SEQUENCE ANALYSIS. 
Amplification of the RT-encoding region of the pot gene was 
performed using the Perkin-Elmer/Cetus GeneAMP PGR protocol. 
Each 100 jil reaction contained 10 mM Tris-HGI, pH 8.3, 50 mM KGI, 
200 |iM of each dNTP (dATP, dGTP, dGTP and dTTP), 4 mM MgGl2, 0.2 
|a.M of each primer, 2.5 Units of AmpHTaq ® DNA polymerase, and 10 
to 20 |ig of target DNA. Reactions were overlaid with 50-100 jil of 
light mineral oil. The sense primer (5'-GTA ATG TTT GTG TGT TAG 
AAG ATA AGT G-3') and the reverse complement primer (5'-ATG ATA 
TGG TGG ATG TTG TGA GGT-3') were synthesized in the Murdock 
Molecular Biology Facility, University of Montana, Missoula, MT. 
These primers were chosen to amplify a 1763-base pair fragment 
that contained nucleotides 2268 through 4031. The PGR was run for 
30 cycles, each cycle comprised of 30 seconds of denaturation at 
94° G, 30 seconds of annealing at 62° G and two minutes of 
extension at 72° G. After PGR, product was visualized on an agarose 
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gel. For this, the mineral oil was separated from the PGR products 
and an aliquot of the mixture was run on a 0.8% low-melting 
agarose electrophoresis gel in 40 mM Tris acetate, pH 7.6, 
containing 1 mM EDTA (61). The agarose gel and running buffer 
contained 0.5 |ig/ml ethidium bromide. A 1763-base pair band was 
identified by comparing the electrophoresed PGR reaction to a 1 Kb 
DNA ladder (Gibco BRL, Gaithersburg, MD). The remaining PGR product 
was purified using the QIAquick PGR Purification Kit, Qiagen Inc., 
Ghatsworth, GA. Sequencing was performed in the forward and 
reverse directions with two or more primers covering each 250-
base pair section of the RT-encoding region along with small 
flanking regions on either end of RT. Four different primers were 
used to sequence the 2474 region containing the point mutation. This 
DNA was directly sequenced by Joan Strange, The Murdock Molecular 
Biology Facility, The University of Montana, Missoula, MT, with a Taq 
Dye Deoxy™ Terminator sequencing kit and analyzed on a Model 373A 
automated DNA sequencer (Applied Biosystems, Foster Gity, GA). 
REVERSION STUDIES. The stability of the d4T-resistant 
phenotype was determined for D4R-3c and D4R-4c. These mutants 
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were passaged in the absence of d4T. CrFK cells were infected with 
D4R-3C, or D4R-4c and maintained without d4T. When virus 
production was apparent (about two weeks), an IC50 for d4T was 
determined by FIA. The resulting viruses were used to initiate a 
subsequent round of infection. Each virus was passaged three times 
in the absence of d4T. 
SITE-DIRECTED MUTAGENESIS. To facilitate mutational analysis, 
we constructed a 34pol cassette virus from the infectious molecular 
clone, FIV 34TF10 (56). This was constructed by modification of the 
EcoR1 site in the polylinker of FIV 34TF10, enabling use of the 
natural EcoR1 site of the virus for the pol cassette. The EcoR1 site 
in the polylinker was changed from GAATTC to GAATTG. This 
modification was achieved by PGR using four synthetic primers. 
Primer #144 was the most 5' and spanned the Dralll site of the 
pUG119 portion of 34TF10 clone (5'-GAT TGG GTG TGA TGG TTC AGG 
TAG TGG G-3'). Primer #145 was an antisense primer that spanned 
the Eco R1 site of the vector's polylinker and changed this site (5'-
GAA TTG ACT GGC CGT CGT CGT TTT AC-3', base change underlined). 
Primer #146 was a sense primer that matched primer #145 at the 
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Eco R1 site and was also designed to alter the natural EcoR^ site 
(5'-GTA AAA CGA CGG GCC AGT ÇAA TTC-3', base change underlined). 
Primer #147 was the most 3' and spanned the Sac! site of the virus 
(5'-CAA CTT GAT TAT GGA GOT CGA TG-3'). Primer pairs #144 / 
#145 and #146 / #147 were used for PGR to amplify DNA from the 
34TF10 target. Amplified DNA products were gel-purified, combined, 
and reamplified using primers #144 and #147. The resulting PGR 
product and 34TF10 were cleaved with Dralll and Sac\ and the 
digests were gel-purified then ligated. The desired mutation was 
confirmed by sequence analysis. After transfection into CrFK cells, 
34pol cassette produced FIV that was indistinguishable from FIV 
34TF10. 
To introduce the mutation at codon 47 of the FIV RT, an 1164-bp 
fragment corresponding to nucleotide 1740-2904 was amplified 
using primer #16 (GAT CCT ATA TA A ATG TCA TCC) and primer #41 
(GGA TCA GGA CCA GTG TGT). Amplification was performed using the 
Perkin-Elmer/Cetus GeneAMP PCR protocol. Each 100 |il reaction 
contained 10 mM Tris-HCI, pH8.3, 50 mM KCI, 200 |ilVI of each dNTP 
(dATP, dCTP, dGTP and dTTP), 4 mM MgCb, 0.2 |iM of each primer, 2.5 
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Units of AmpHTaq ® DNA polymerase, and 10 to 20 p.g of target DNA. 
Reactions were overlaid with 50-100 p,l of light mineral oil. The 
PGR was run for 30 cycles, each cycle comprised of 30 seconds of 
denaturation at 94° G, 30 seconds of annealing at 52° G and two 
minutes of extension at 72° G. After PGR, product was visualized on 
an agarose gel. For this, the mineral oil was separated from the PGR 
products and an aliquot of the mixture was run on a 0.8% low-
melting agarose electrophoresis gel in 40 mM Tris acetate, pH 7.6 
containing 1 mM EDTA (61). The agarose gel and running buffer 
contained 0.5 |ig/ml ethidium bromide. The PGR product and 34pol 
cassette were each cleaved with EcoRI and Nsi\. The reaction 
contained 10X A/s/l buffer, 24 U EcoRI, 30 U Nsi\ and 3.6 mg of the 
PGR product (including FIV 34TF10 or D4R-3c DNA) and then 
incubated 3 hours at 37° G. The fragments were gel-purified by gene 
cleaning. First, the gel slices were cut, and weighed. Then 3 volume 
of sodium iodide were added and incubated 5 min at 45-55 °G. 5 |il 
of glassmilk was added and incubated at room temperature for 30 
min. After centrifugation, pellets were washed three times with 
NEW wash (ethanol, both glassmilk and NEW wash are from BIO 101 
gene-clean kit) and eluted with 20 )il of water. OD260 was measured. 
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The resulting 803-bp fragment from D4R-3c, corresponding to 
nucleotide 1871-2674 of the FIV genome, was ligated into the 
cleaved 34pol cassette by using \^ector:insert ratio 1:4, adding T4 
DNA ligase and incubating overnight at 16° C. DNA sequence analysis 
was used to confirm the presence of the desired mutation. Only one 
ligation product contained the 2474 point mutation. This construct 
was transformed into the J5 strain of E. coli JM109 and the 
resulting plasmid DNA was used to transfect CrFK cells for 
production of virus. 
RESULTS 
SELECTION OF d4T-RESISTANT MUTANTS. In initial 
experiments, we attempted to obtain d4T-resistant mutants of FIV 
by selection in the continuous presence of a high concentration of 
d4T (100 |iM, which is approximately 8 times the IC50 for FIV). This 
approach, which we call "blast" selection, had been successful for 
selection of FIV mutants resistant to AZT (57,58), ddl (21) or ddC 
(43). However, in attempts to select with 100 |iM d4T, we were 
unable to obtain any d4T-resistant mutants. Virus obtained after 
this selection had wild type susceptibility to d4T. Therefore, we 
switched to a step-wise selection protocol that is similar to that 
used by Gao et al. (19,20) and by Larder et al. (36) to select drug-
resistant variants of HIV-1. The initial round of selection was 
carried out with 12.5 |j.M d4T, which is equivalent to the IC50 of d4T 
for FIV (58). The concentration of d4T was then increased 2-fold in 
each subsequent round. For the first round of selection, two 25 cm2 
flasks of 60% confluent CrFK cells were pre-treated with 12.5 |iM 
d4T for 1 h prior to infection to ensure that the drug had been 
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converted to its active form by the cells. Then the drug pre-treated 
CrFK cells were infected with a cell-free culture supernatant of FIV 
34TF10 at an input multiplicity of approximately 2000 focus 
forming units (FFU). Media and drug were replaced every 48 hours, 
and cells were removed with trypsin and subcultured as necessary 
(usually every week). Cultures were monitored weekly for the 
presence of virus by the FIA. By 2 to 3 weeks post-infection virus 
production was apparent. 
For the second round of selection, culture supernatants (cell-
free) from each of the first-round cultures (approximately 2000 FFU 
also) were used to infect flasks of CrFK cells in the presence of 25 
|iM d4T. They were maintained with 25 |xM d4T and monitored for 
virus production as before. Using these protocols, virus was 
subsequently passaged in 50 and 100 iiM d4T, In each round of 
selection, virus production was apparent by 2 to 3 weeks post­
infection. After passage in 100 |iM d4T, dose response curves were 
performed for preliminary screening of the d4T-resistant phenotype. 
Two d4T-resistant mutants, designated D4R-1c and D4R-2c, were 
obtained. These mutants were resistant to d4T (Fig. 5). At this point 
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Fig 5. Inhibition of FIV 34TF10, D4R-1c and D4R-2c by d4T as 
determined by FIA. Results are from two experiments and each point 
represent four determinations. Bars represent standard error of the 
mean, and are omitted where the standard error was too small to 
accurately show using error bars. 
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plaque-purification of mutant viruses were initiated. 
PLAQUE-PURIFICATION OF d4T-RESISTANT MUTANTS. To 
minimize potential heterogeneity within the d4T-resistant mutant 
populations, the FIA was used to isolate a clone of virus that had 
descended from a single infectious particle. A focus of infection 
represents an infection by a single virion (Fig. 6). 
Fig 6. Focus of FIV-infected CrFK cells detected with the 
immunostaining procedure described in methods. 
CrFK cells were seeded at a density of 1.0 X 104 cells per well in 
TC24 plates, with 100 |iM d4T, and were infected with virus stocks 
(D4R-1C and D4R-2c) that had been diluted to contain approximately 
one infectious particle per well. After six days, culture 
supernatants were transferred to uninfected cells with 100 |a,M d4T 
in TC24 plates, and the original plates were immunostained to 
identify those wells that contained a single focus of infection. Cells 
infected with progeny from a single infection event were 
transferred along with supernatant to a flask and maintained with 
100 fiM d4T and monitored for virus production by the FIA. Two 
plaque-purified mutants, designated D4R-3c and D4R-4c (obtained 
from D4R-1C and D4R-2c, respectively) were selected for further 
characterization. Both plaque-purified mutants retain the d4T-
resistant phenotype of the parent populations (Fig. 7). 
The d4T-resistance of the D4R-1c, D4R-2c, D4R-3c and D4R-4c 
were confirmed with the FIA by determining the number of foci at 
varying concentrations of d4T. The dose response curves shown in 
Fig. 5 and Fig. 7 verify that D4R-1c, 2c and D4R-3c, 4c were 
considerably less sensitive to inhibition by d4T than the molecular 
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d4T DOSE RESPONSE CURVE FOR D4R-3c, AND 4c 
100 -1 
80 -
o 
o 
60 -
_I 
o 
Q: 
Z 
O 40 -
O 
34TF10 
D4R-3C 
20 -
D4R-4C 
10 100 
[d4T] \iM 
Fig 7. Inliibition of FIV 34TF10 and D4R-3c and 4c by d4T as 
determined by FIA. Results are from three experiments and each 
point represent four determinations. Bars represent standard error 
of the mean, and are omitted where the standard error was too small 
to accurately show using error bars. 
clone of FIV. The IC50 value for inhibition of D4R-1c and 2c by 
d4T were greater than 36 |iM compared to 12 for FIV 34TF10. 
Similar results were determined with D4R-3c and D4R-4c. These 
data demonstrated that these mutants were at least 3 to 6-fold less 
susceptible to d4T than FIV 34TF10. 
CHARACTERIZATION OF d4T-RESISTANT MUTANTS. 
Susceptibility to antiviral compounds. The susceptibility of 
D4R-3C and D4R-4c to a variety of other antiviral compounds was 
determined using the FIA and compared to the susceptibilities of FIV 
34TF10 (Fig 8. and Table. 1). These data showed that D4R-3c and 
D4R-4C were cross-resistant to several other antiviral compounds. 
Both mutants were 2 to 2.5-fold resistant to AZT, 5 to 6-fold 
resistant to FLT, 2-fold to ddC, 1 to 2 fold to ddl and 4-fold to PMEA. 
They were also highly resistant (>50-fold) to the non-nucleoside 
inhibitor, PFA. 
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Fig 8. Inhibition of FIV 34TF10 and D4R-3c and 4c by various 
antivirals as determined by FIA. Results are from three experiments 
and each point represent four determinations. Bars represent 
standard error of the mean, and are omitted where the standard 
error was too small to accurately show using error bars. 
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Table 1. Sensitivities of FIV 34TF10 and d4T-resistant mutants 
derived from it to antiviral compounds as determined by FIAa 
MEAN IC50 + SE 
Compound FIV 34TF10 D4R-3c D4R-4c 
d4T 9 ± 2 34 ±8 32 ± 7 
AZT 0.3 ±0.1 0.8 ±0.1 0-7 ± 0.1 
FLT 0.2 ± 0.05 1.1 ± 0.1 1.3 ± 0-1 
ddC 4.4 ± 0.3 9.1 ± 1.5 9 ± 2.1 
ddl 1.1 ± 0.04 2.4 ± 0.4 1.5 ± 0 
PFA 207 ± 44 >10,000 >10,000 
PMEA 0.1 ± 0 0.4 ± 0.02 0.4 ± 0-02 
^Values are from two or more experiments, with four 
determinations per experiment. 
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Reverse transcriptase. Reverse transcriptase was purified from 
D4R-3C and from wild-type FIV (recombinant RT) (46). This wild-
type FIV RT was produced in Escherichia coli, and has been shown to 
be similar to virion-derived FIV RT in its susceptibility to several 
antiviral nucleotides. The kinetic parameters of inhibition by d4TTP 
were determined for D4R-3c RT and compared to wild-type FIV RT. 
The two enzymes were nearly identical in Km for dTTP (5.8 ±0.6 |j,M). 
However, the Kj for inhibition of RT from D4R-3c by d4TTP, 4 7 nM, 
was 3-times higher than that of wild-type FIV RT. Furthermore, the 
Ki values for inhibition of this mutant enzyme and R-RT by AZTTP 
and PFA were determined. As expected, AZTTP and d4TTP displayed 
competitive inhibition of the enzymes and PFA displayed non­
competitive inhibition (Fig. 9). The inhibition constant of mutant RT 
by AZTTP, 21 nM, was 10-times higher than that of wild-type FIV RT 
and by PFA,1.7 |iM, was 6-times higher than for inhibition of the 
wild-type FIV RT, respectively (Table 2). 
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Table 2. Kinetic Constants for wild-type FIV and D4R -3c RTs a 
Ki rnM^ 
Inhibitor FIV 34TF10 RT D4R-3c-RT 
d4TTP 1.4 + 0.14 4.7 + 0.16 
AZTTP 2.2 ± 0.23 21 + 1.51 
RFA 265 ± 37 1720 + 345 
^Values are reported as the mean + SEM of at least five 
determinations. The mode of inhibition of each enzyme by d4TTP or 
by AZTTP was competitive with respect to substrate. Inhibition of 
each enzyme by PFA was non-competitive with respect to substrate. 
The Km for dTTP was 5.8 + 0.6 jiM for each enzyme. 
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Fig 9. Determination of K, values for inhibition of wild-type FIV RT 
and D4R-3C RT. Values reported are averages from duplicate 
determinations. 
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Nucleotide sequence analysis. DNA sequence analysis of the 
entire RT-encodIng region of the pol gene from D4R-3c and FIV 
34TF10 were perfornned in the forward and reverse directions. FIV 
34TF10 DNA had been subcloned into the plasmid pUC119 and was 
used as the wild-type control. These analyses revealed only a single 
point mutation, a G to A base change, at position 2474 of the FIV pol 
gene. This substitution results in the replacement of Val-47 with 
lie, named 147. The nucleic acid and amino acid sequences of FIV 
34TF10 and D4R-3c pol gene are shown in Fig. 10 
lyAsnValCy sValLeuGlu AspAsnSerL euIleGlnPr oLeuLeuGly ArgAspAsnM etIleLysPh 
GTAATGTTTG TGTCTTAGAA GATAACTCAT TAATACAACC ATTATTGGGG AGAGATAATA TGATTAAATT 2310 
plasmid 
FIV3 4TF10 
D4R- 3 C  
>rt 5 10 15 
eAsnlleArg LeuValMetA laGlnlleSe rAspLysIle ProValValL ysValLysMe tLysAspPro 
CAATATTAGG TTAGTAATGG CTCAAATTTC TGATAAGATT CCAGTAGTAA AAGTAAAAAT GAAGGATCCT 2380 
plasmid 
FIV3 4TF10 
D4R- 3 C  
Figure 10. (cont. on next page) 
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20 25 30 35 
AsnLysGlyP roGlnlleLy sGlnTrpPro LeuThrAsnG luLysIleGl uAlaLeuThr GluIleValG 
AATAAAGGAC CTCAAATAAA ACAATGGCCA TTAACAAATG AAAAAATTGA AGCCTTAACA GAAATAGTAG 2450 
plasmid 
FIV34TF10 
D4R- 3 C  
40 45 50 55 60 
luArgLeuGl uLysGluGly LysValLysA rgAlaAspSe rAsnAsnPro TrpAsnThrP roValPheAl 
AAAGACTAGA AAAAGAAGGG AAAGTAAAAA GAGCAGATTC AAATAATCCA TGGAATACAC CAGTATTTGC 2 52 0 
plasmid 
FIV34TF10 
A D4R-3c 
He 
65 70 75 80 85 
alleLysLys LysSerGlyL ysTrpArgMe tLeuIleAsp PheArgGluL euAsnLysLe uThrGluLys 
TATAAAAAAG AAAAGTGGAA AATGGAGAAT GCTCATAGAT TTTAGAGAAT TAAACAAATT AACTGAGAAA 2590 
plasmid 
FIV34TF10 
D4R- 3 C  
90 95 100 105 
GlyAlaGluV alGlnLeuGl yLeuProHis ProAlaGlyL euGlnlleLy sLysGlnVal ThrValLeuA 
GGAGCAGAGG TCCAGTTGGG ACTACCTCAT CCTGCTGGTC TACAAATAAA AAAACAAGTA ACAGTATTAG 2660 
plasmid 
FIV34TF10 
D4R- 3 C  
110 115 120 125 130 
spIleGlyAs pAlaTyrPhe ThrlleProL euAspProAs pTyrAlaPro TyrThrAlaP heThrLeuPr 
ATATAGGGGA TGCATATTTC ACCATTCCTC TTGATCCAGA TTATGCTCCT TATACAGCAT TTACTTTACC 273 0 
plasmid 
FIV34TF10 
D4R- 3 C  
Figure 10. (cont. on next page) 
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135 140 145 150 155 
oArgljysAsn AsnAlaGlyP roGlyArgAr gPheValTrp CysSerLeuP roGlnGlyTr pIleLeuSer 
TAGGAAAAAT AATGCGGGAC CAGGAAGGAG ATTTGTGTGG TGTAGTCTAC CACAAGGCTG GATTTTAAGT 2800 
plasmid 
FIV34TF10 
D4R- 3 C  
160 165 170 175 
ProLeuIleT yrGlnSerTh rLeuAspAsn IlelleGlnP roPhelleAr gGlnAsnPro GlnLeuAspI 
CCATTGATAT ATCAAAGTAC ATTAGATAAT ATAATACAAC CTTTTATTAG ACAAAATCCT CAATTAGATA 287 0 
plasmid 
FIV34TF10 
D4R- 3 C  
180 185 190 195 200 
leTyarGlnTy rMetAspAsp IleTyrlleG lySerAsnLe uSerLysLys GluHisLysG luLysValGl 
TTTACCAATA TATGGATGAC ATTTATATAG GATCAAATTT AAGTAAAAAG GAGCATAAAG AAAAGGTAGA 294 0 
plasmid 
FIV34TF10 
D4R- 3 C  
205 210 215 220 225 
uGluLeuArg LysLeuLeuL euTrpTrpGl yPheGluThr ProGluAspL ysLeuGlnGl uGluProPro 
AGAATTAAGA AAATTACTAT TATGGTGGGG ATTTGAAACT CCAGAAGATA AATTACAGGA AGAACCCCCA 3 010 
plasmid 
FIV34TF10 
D4R- 3 C  
230 235 240 245 
TyrThrTrpM etGlyTyrGl uLeuHisPro LeuThrTrpT hrlleGlnGl nLysGlnLeu AspIleProG 
TATACATGGA TGGGTTATGA ATTACATCCA TTAACATGGA CAATACAACA GAAACAGTTA GACATTCCAG 3 080 
plasmid 
FIV34TF10 
D4R- 3 C  
Figure 10. (cont. on next page) 
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250 255 260 265 270 
luGlnProTh rLeuAsnOlu LeuGlnLysL euAlaGlyLy sIleAsnTrp AlaSerGlnA lalleProAs 
AACAGCCCAC TCTAAATGAG TTGCAAAAAT TAGCAGGAAA AATTAATTGG GCTAGCCAAG CTATTCCAGA 3150 
plasmid 
FIV34TF10 
D4R- 3 C  
275 280 285 290 295 
pLeuSerlle LysAlaLeuT hrAsnMetMe tArgGlyAsn GlnAsnLeuA snSerThrAr gGlnTrpThr 
CTTGAGTATA AAAGCATTAA CTAACATGAT GAGAGGAAAT CAAAACCTAA ATTCAACAAG ACAATGGACT 322 0 
plasmid 
FIV34TF10 
D4R- 3 C  
300 305 310 315 
LysGluAlaA rgLeuGluVa IGlnLysAla LysLysAlal leGluGluGl nValGlnLeu GlyTyrTyrA 
AAAGAAGCTC GACTGGAAGT ACAAAAGGCA AAAAAGGCTA TAGAAGAACA AGTACAACTA GGATACTATG 3290 
plasmid 
FIV3 4TF10 
D4R- 3 C  
320 325 330 335 340 
spProSerLy sGluLeuTyr AlaLysLeuS erLeuValGl yProHisGln IleSerTyrG InValTyrGl 
ACCCCAGTAA GGAGTTATAT GCTAAATTAA GTTTGGTGGG ACCACATCAA ATAAGTTATC AAGTATATCA 3360 
plasmid 
FIV34TF10 
D4R- 3 C  
345 350 355 360 365 
nLysAspPro GluLysIleL euTrpTyrGl yLysMetSer ArgGlnLysL ysLysAlaGl uAsnThrCys 
GAAGGATCCA GAAAAGATAC TATGGTATGG AAAAATGAGT AGACAAAAGA AAAAGGCAGA AAATACATGT 3 43 0 
plasmid 
FIV34TF10 
D4R- 3 C  
Figure 10. (cont. on next page) 
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3 7 0  3 7 5  3 8 0  3 8 5  
AspIleAlaL euArgAlaCy sTyrLysIle ArgGluGluS erIlelleAr glleGlyLys GluProArgT 
GATATAGCCT TAAGAGCATG CTATAAGATA AGAGAAGAGT CTATTATAAG AATAGGAAAA GAACCAAGAT 3  5 0 0  
plasmid 
FIV34TF10 
D4R- 3 C  
390 395 400 405 410 
yrGluIlePr oThrSerArg GluAlaTypG luSerAsnGl uIleAsnSer ProTyrLeuL ysAlaProPr 
ATGAAATACC TACTTCTAGA GAAGCCTGGG AATCAAATTT AATTAATTCA CCATATCTTA AGGCCCCACC 3 57 0 
plasmid 
FIV34TF10 
D4R- 3 C  
415 420 425 430 435 
oProGluVal GluTyrlleH isAlaAlaLe uAsnlleLys ArgAlaLeuS erMetlleLy sAspAlaPro 
TCCTGAGGTA GAATATATCC ATGCTGCTTT GAATATAAAG AGAGCGTTAA GTATGATAAA AGATGCTCCA 3 640 
plasmid 
FIV34TF10 
D4R- 3 C  
440 445 450 455 
IleProGlyA laGluThrTr pTyrlleAsp GlyGlyArgL ysLeuGlyLy sAlaAlaLys AlaAlaTyrT 
ATACCAGGAG CAGAAACATG GTATATAGAT GGAGGTAGAA AGCTAGGAAA AGCAGCAAAA GCAGCCTATT 3710 
plasmid 
FIV34TF10 
D4R- 3 C  
4 6 0  4 6 5  4 7 0  4 7 5  4 8 0  
rpThrAspTh rGlyLysTrp ArgValMetA spLeuGluGl ySerAsnGln LysAlaGluI leGlnAlaLe 
GGACAGATAC AGGAAAGTGG CGAGTGATGG ATTTAGAAGG CAGTAATCAG AAGGCAGAAA TAGAAGCATT 3 7  8 0  
-A plasmid 
- A  FIV34TF10 
_A D4R- 3 C  
G lu 
Figure 10. (cont. on next page) 
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485 490 495 500 505 
uLeuLeuAla LeuLysAlaG lySerGluGl uMetAsnlle IleThrAspS erGlnTyrVa lIleAsnlle 
ATTATTGGCA TTAAAAGCAG GATCAGAGGA AATGAATATT ATAACAGATT CACAATATGT TATAAATATT 3 850 
plasmid 
FIV34TF10 
D4R- 3 C  
510 515 520 525 
IleLeuGlnG InProAspMe tMetGluGly IleTrpGlnG luValLeuGl uGluLeuGlu LysLysThrA 
ATTCTTCAAC AACCAGATAT GATGGAGGGA ATCTGGCAAG AAGTTTTAGA AGAATTGGAG AAGAAAACAG 3 920 
plasmid 
FIV34TF10 
D4R- 3 C  
530 535 540 545 550 
lallePhell eAspTrpVal ProGlyHisL ysGlyllePr oGlyAsnGlu GluValAspL ysLeuCysGl 
CAATATTTAT AGATTGGGTC CCAGGACATA AAGGTATTCC AGGAAATGAG GAAGTAGATA AGCTTTGTCA 3 990 
plasmid 
FIV34TF10 
D4R- 3 C  
555 <rt 560 565 
xiThrMetMet IlelleGluG lyAspGlyll eLeuAspLys ArgSerGluA spAlaGlyTy rAspLeuLeu 
AACAATGATG ATAATAGAAG GGGATGGGAT ATTAGATAAA AGGTCAGAAG ATGCAGGATA TGATTTATTA 4060 
plasmid 
FIV3 4TF.10 
D4R- 3 C  
Fig. 10 Nucleotide sequence and deduced amino acid sequence of RT-
encoding region of pol gene from FIV 34TF10 clone of FIV in 
pUC119, virus derived from this molecular clone and D4R-3c. 
denotes identity. 
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Reversion studies. In order to determine whether this 147 
mutation was genetically stable, CrFK cells were infected with 
D4R-3C and D4R-4c and maintained in the absence of d4T. When virus 
production was apparent, an IC50 for d4T were determined, and these 
viruses were used to initiate a subsequent round of infection. This 
experiment was carried out for three rounds of infection. Both 
viruses remained d4T-resistant even after three rounds without d4T 
(Table. 3). These data demonstrated that the d4T-resistant 
phenotype is stable. 
Site-directed mutagenesis. In order to confirm the role of this 
mutation in d4T-resistance, the G to A mutation at position 2474 
was introduced into the FIV 34pol cassette by site-directed 
mutagenesis. Initial attempts to obtain a 1297-bp fragment from 
D4R-3C proviral DNA with primers #28 and #16 were not successful. 
Therefore, we switched to primers #41 (GGATCAGGACCAGTGTGT) 
and #16 (GAT CCT AT AT AAAT GT CAT CC) and obtained an 1164-bp 
fragment containing position 2474. This fragment and 34pol 
cassette were each cleaved with EcoRI and Nco\, and ligated. After 
transforming them into the J5 strain of E. coli JM109, there were no 
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Table 3. Phenotypic stability of d4T-resistant mutants when 
passaged in the absence of d4T a 
Virus MEAN IC50 (iliM) ± SEM 
Roundl Round2 Round3 
34TF10 12.8 ± 2.8 16 ± 2.7 14 ± 3.1 
D4R-3C 24.5 ± 5.5 33 ± 3.3 63 ± 26 
D4R-4C 38 ± 13 24 ± 4.8 41.3+12 
^Values are from two or more experiments with four determinations 
per experiment. 
colonies. EcoRI and Nsi\ were then used in a second attempt, and 
five colonies were obtained. DNA sequence analysis revealed that 
one colony had the correct insert containing the 147 mutation. This 
DNA was transfected into CrFK cells. When virus was apparent, an 
IC50 for d4T was determined. The mutant made by site-directed 
mutagenesis was 2.5-fold resistant to d4T, confirming the role of 
this mutation in d4T-resistance. 
DISCUSSION 
The results of this study have demonstrated the in vitro selection 
and characterization of d4T-resistant mutants of FIV. This was the 
first d4T-resistant mutant derived from a molecular clone of either 
FIV or HIV-1. We initially attempted to select d4T-resistant 
mutants with a "blast" protocol. Using this method, AZT, ddl and 
ddC-resistant mutants of FIV were successfully selected. However, 
we were unable to obtain any d4T-resistant mutants from this type 
of selection. The virus that was obtained after passaged in 100 |j,M 
d4T was quickly apparent after 1 to 2 weeks, and was as susceptible 
to d4T as the wild-type strain, FIV 34TF10. The reason for this 
may be incomplete inhibition of wild-type virus. Therefore, we 
switched to a step-wise selection protocol, and succeeded in 
selection of d4T-resistant mutants of FIV. 
The d4T-resistant mutants we have isolated have relatively low 
level, i.e. 3- to 6-fold, resistance to d4T. This level of resistance is 
similar to that reported by Lacey and Larder for a d4T-resistant 
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mutant of HIV-1, which displayed 7-fold resistance (33). Relatively 
low level resistance has also been observed with mutants for FIV or 
HIV-1 resistant to ddl or ddC. For example, a ddl-resistant mutant of 
FIV displayed a 2 to 4-fold less susceptibility to ddl (21), ddC-
resistant mutant of FIV was 3 to 6-fold resistant to ddC (43), and 
the HIV-1 mutants resistant to ddl or ddC range from 4 to 6-fold 
resistant (18,19,20,23,64). In contrast, many of the AZT-resistant 
mutants of FIV (57,58) or HIV-1 (35,36,37) displayed greater than 
40-fold resistance to AZT. 
The plaque-purified d4T-resistant mutants we have isolated are 
cross-resistant to ddl and ddC. In this respect they are 
phenotypically similar to the d4T-resistant mutant of HIV-1 
reported by Lacey and Larder (33). The d4T-resistant mutants of FIV 
were also cross-resistant to AZT, FLT, PMEA and PFA. However, 
Lacey and Larder reported that the d4T-resistant mutant of HIV-1 
remained sensitivity to AZT and they did not determine FLT, PMEA 
and PFA. 
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Reverse transcriptases were purified from wild-type and the 
plaque-purified d4T-resistant mutant (D4R-3c) of FIV. The RT from 
the mutant virus was resistant to the active form of d4T, d4TTP. 
The mutant enzyme had a 3-fold higher Kj for d4TTP than the wild-
type FIV RT, whereas the two enzymes were identical in K m for the 
substrate, dTTP. This 3-fold resistance at the enzyme level 
correlates well with the 3- to 6-fold resistance at the level of 
virus replication. Moreover, we found that D4R-3c RT also had 
decreased susceptibility to inhibition by AZTTP or PFA. 
Interestingly, the level of the RT resistance to AZTTP was greater 
than the level of resistance to AZT of virus replication. A similar 
lack of correlation between virus susceptibility to AZT and RT 
susceptibility to AZTTP has been shown for many AZT-resistant 
mutants of HIV-1 and FIV, which have RTs that are not even 
resistant to AZTTP (36,37,57). 
The resistance shown by the RT from D4R-3c is due to a mutation 
in the RT-encoding region of the FIV pol gene. Sequence analysis of 
the plaque-purified d4T-resistant mutant of FIV revealed a single 
point mutation resulting in an amino acid change from valine to 
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isoleucine at codon 47 of FIV RT. This nucleotide substitution at 
position 2474 in D4R-3c was the only divergence from the wild-type 
RT-encoding region. The d4T-resistant mutant of HIV-1 that has 
been characterized was mapped to codon 75 of the HIV-1 RT (33), 
and there have been no drug-resistant mutants of HIV-1 or FIV RTs 
that map to codon 47 (62). Interestingly, the amino acid found at 
codon 47 of RT from the d4T-resistant mutant of FIV (isoleucine) is 
the amino acid present at codon 47 of wild-type HIV-1 RT. It will be 
interesting to determine whether alteration of codon 47 in the HIV-
1 RT will affect susceptibility of HIV-1 to d4T or other RT-targeted 
antiviral drugs. 
Some AZT-resistant mutants of FIV that phenotypically revert 
very rapidly when they replicate in the absence of AZT (58). In 
contrast, D4R-3c (like a ddC-resistant mutant of FIV, DCR-5c) (43) 
remained phenotypically stable when passaged in the absence of d4T, 
even after three passages. This genetic stability makes D4R-3c a 
better candidate than the genetically unstable mutants for future in 
vivo studies to evaluate how mutations conferring drug-resistance 
affect pathogenicity of the virus. 
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The structure of HIV-1 RT has been determined by X-ray 
crystallography (29,31). Many reports have shown crystals of RT 
suitable for structural analysis. HIV-1 RT contained two subunits, 
p66 and p51. The p66 subunit is folded into five separate 
subdomains, the RNase H domain and four subdomains of the pol 
domain, termed fingers, palm, thumb and connection. p51 has the 
same amino acid sequence and subdomains, but the conformation of 
the pol domain is astonishingly different from that of p66 (31). 
Based upon the X-ray crystal structure of HIV-1 RT and the amino 
acid sequence homology of the HIV-1 and FIV RTs, codon 47 is 
predicted to be in the "fingers domain" of RT. On the p66 subunit 
this is on the outside of the "fingers domain", whereas the active 
site of the enzyme is on the opposite, or inner side of the "fingers". 
However, position 47 of the p51 subunit is adjacent to the active 
site of the p66 subunit, in a position where a mutation of this amino 
acid could affect drug susceptibility. Based upon the available 
structural data, we predict that the mutation in codon 47 of the p51 
subunit is responsible for the altered susceptibility of RT to several 
nucleotide analogs. 
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Due to the emergence of mutants resistant to any of the drug used 
in monotherapy, much effort is currently focused upon evaluation of 
combinations of two or more drugs. Recently, chemotherapy of HIV 
infections, as for other chronic infections and malignant diseases, 
is moving into the direction of multiple drug combinations. The 
major advantages of this is: non-overlapping toxicities, reduced risk 
of viral-drug resistance development, and the possibility of 
synergistic combinations. The demonstration that d4T-resistant FIV 
has decreased susceptibility to several other RT inhibitors suggests 
that mutants resistant to the combination of d4T with another RT 
inhibitor may arise readily. Thus, d4T may not be suitable for use in 
these multiple drug combinations. 
CONCLUSION 
Two d4T resistant mutants (D4R-1c, D4R-2c) were successfully 
obtained by step-wise selection with 100 |iM final d4T 
concentration. D4R-1c and 2c were plaque-purified and the resulting 
viruses, designated D4R-3c and 4c. All of these mutants were at 
least 3-fold resistant to d4T as compared to FIV 34TF10. They were 
also cross-resistant to AZT, FLT, ddC, ddl, and PMEA, and were 
highly resistant to PFA. Purified D4R-3c RT was 3-fold resistant to 
d4TTP, 10-fold to AZTTP and 6-fold to PFA, relative to wild type 
FIV RT. A single point mutation was found in the d4T-resistant 
mutant (D4R-3c) that resulted in the amino acid substitution of He 
for Val at codon 47 of the FIV RT. The phenotype of d4T-resistant 
mutants was stable, as D4R-3c and D4R-4c remained d4T-resistant 
even after passage in the absence of d4T for three rounds. The role 
of the V to I mutation at codon 47 in d4T-resistance was confirmed 
by site-directed mutagenesis. 
Future studies should evaluate whether multiple-drug resistant 
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mutants will arise more rapidly with combinations containing d4T. 
It will also be important to examine pathogenicity of d4T-resistant 
FIV, and other FIV drug-resistant mutants, in cats. 
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